Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):e60–e71. doi: 10.1097/QAI.0b013e318245d3c1

Table 3.

Mortality and Loss to Follow-up during the Study Period (per 100 person-years in care)

Barbados (n=560) DR (n=1207) Haiti (n=4717) Jamaica (n=476) Martinique (n=325) Trinidad (n=725) Puerto Rico (n=193) Combined (n=8203)
Median Follow-up Time and Patient Status
Median Follow-up (Months) 52 (33, 70) 20 (9, 33) 27 (13, 49) 40 (28, 47) 39 (21, 60) 48 (37, 59) 35 (10, 63) 31 (14, 50)
Alive or Transferred 434 (78) 871 (72) 3517 (75) 361 (76) 290 (89) 593 (82) 56 (29) 6122 (75)
Deceased 85 (15) 181 (15) 598 (13) 38 (8) 21 (6) 78 (11) 47 (24) 1048 (13)
Lost to Follow-up 41 (7) 155 (13) 602 (13) 77 (16) 14 (4) 54 (7) 90 (47) 1033 (13)
Mortality
3 months 13.9 34.2 21.8 10.8 3.8 17.2 6.8 20.9
6 months 10.8 23.8 15.7 6.4 5.1 10.8 8.3 14.8
1 year 8.1 15.5 10.1 3.8 3.6 6.5 7.0 9.6
3 years 4.6 8.9 5.9 3.2 2.3 3.2 6.7 5.5
5 years 3.8 8.4 5.0 2.7 2.1 2.8 6.9 4.7
Loss to Follow-up
6 months 1.1 15.1 16.7 16.1 3.8 3.5 39.1 14.0
1 year 1.3 10.5 10.7 10.6 2.6 3.7 26.8 9.3
3 years 2.1 7.2 6.1 6.5 1.6 2.1 15.7 5.5
5 years 1.7 7.2 5.1 5.5 1.3 2.0 14.6 4.7